Open AccessSuccessful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
Author(s) -
Ling Peng,
Kui Xiao,
Jian Cui,
Xianghua Ye,
Yongchang Zhang,
Li Mao,
Giovanni Selvaggi,
Jennifer Yen,
Justin Stebbing
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s310756
Subject(s) - alectinib , medicine , lung cancer , oncology , crizotinib , disease , gastroenterology , malignant pleural effusion
Alectinib is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. Although generally well tolerated, alectinib can cause serious or life-threatening side effects.